PRME Relative Valuation
PRME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRME is overvalued; if below, it's undervalued.
Historical Valuation
Prime Medicine Inc (PRME) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -4.91. The fair price of Prime Medicine Inc (PRME) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 3.85 USD , Prime Medicine Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：3.85
Fair
Undervalued
-3.96
PE
1Y
3Y
5Y
Trailing
Forward
-3.46
EV/EBITDA
Prime Medicine Inc. (PRME) has a current EV/EBITDA of -3.46. The 5-year average EV/EBITDA is -4.07. The thresholds are as follows: Strongly Undervalued below -10.75, Undervalued between -10.75 and -7.41, Fairly Valued between -0.73 and -7.41, Overvalued between -0.73 and 2.61, and Strongly Overvalued above 2.61. The current Forward EV/EBITDA of -3.46 falls within the Historic Trend Line -Fairly Valued range.
-3.17
EV/EBIT
Prime Medicine Inc. (PRME) has a current EV/EBIT of -3.17. The 5-year average EV/EBIT is -4.13. The thresholds are as follows: Strongly Undervalued below -10.75, Undervalued between -10.75 and -7.44, Fairly Valued between -0.82 and -7.44, Overvalued between -0.82 and 2.50, and Strongly Overvalued above 2.50. The current Forward EV/EBIT of -3.17 falls within the Historic Trend Line -Fairly Valued range.
31.09
PS
Prime Medicine Inc. (PRME) has a current PS of 31.09. The 5-year average PS is 138.17. The thresholds are as follows: Strongly Undervalued below -282.13, Undervalued between -282.13 and -71.98, Fairly Valued between 348.32 and -71.98, Overvalued between 348.32 and 558.47, and Strongly Overvalued above 558.47. The current Forward PS of 31.09 falls within the Historic Trend Line -Fairly Valued range.
-4.33
P/OCF
Prime Medicine Inc. (PRME) has a current P/OCF of -4.33. The 5-year average P/OCF is -5.69. The thresholds are as follows: Strongly Undervalued below -12.80, Undervalued between -12.80 and -9.25, Fairly Valued between -2.14 and -9.25, Overvalued between -2.14 and 1.42, and Strongly Overvalued above 1.42. The current Forward P/OCF of -4.33 falls within the Historic Trend Line -Fairly Valued range.
-4.32
P/FCF
Prime Medicine Inc. (PRME) has a current P/FCF of -4.32. The 5-year average P/FCF is -4.86. The thresholds are as follows: Strongly Undervalued below -10.49, Undervalued between -10.49 and -7.67, Fairly Valued between -2.04 and -7.67, Overvalued between -2.04 and 0.78, and Strongly Overvalued above 0.78. The current Forward P/FCF of -4.32 falls within the Historic Trend Line -Fairly Valued range.
Prime Medicine Inc (PRME) has a current Price-to-Book (P/B) ratio of 4.21. Compared to its 3-year average P/B ratio of 3.85 , the current P/B ratio is approximately 9.33% higher. Relative to its 5-year average P/B ratio of 3.61, the current P/B ratio is about 16.52% higher. Prime Medicine Inc (PRME) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -28.08%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -27.25% , the current FCF yield is about -100.00% lower.
4.21
P/B
Median3y
3.85
Median5y
3.61
-18.01
FCF Yield
Median3y
-28.08
Median5y
-27.25
Competitors Valuation Multiple
The average P/S ratio for PRME's competitors is 34.54, providing a benchmark for relative valuation. Prime Medicine Inc Corp (PRME) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 486.12%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PRME increased by 31.85% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 209.00K to 1.23M.
The secondary factor is the Margin Expansion, contributed -83.57%to the performance.
Overall, the performance of PRME in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Prime Medicine Inc (PRME) currently overvalued or undervalued?
What is Prime Medicine Inc (PRME) fair value?
How does PRME's valuation metrics compare to the industry average?
What is the current P/B ratio for Prime Medicine Inc (PRME) as of Dec 05 2025?
What is the current FCF Yield for Prime Medicine Inc (PRME) as of Dec 05 2025?
What is the current Forward P/E ratio for Prime Medicine Inc (PRME) as of Dec 05 2025?